Table 2.
Characteristics of patients with early progression and univariable analysis
| Variable | Overall | Early progression | OR (95% CI) | P | |
|---|---|---|---|---|---|
| No | Yes | ||||
| Age (years) | n = 174 | n = 126 | n = 48 | ||
| Median | 54 | 53 | 57 | 1.03 (1.00, 1.06) | 0.0300 |
| Range | (22‐90) | (22‐83) | (32‐90) | ||
| Age (years) | |||||
| 0‐59 | 121 (69.5%) | 94 (74.6%) | 27 (56.3%) | ‐ | 0.0187 |
| 60+ | 53 (30.5%) | 32 (25.4%) | 21 (43.8%) | 2.28 (1.14, 4.59) | |
| Sex | |||||
| Male | 86 (49.4%) | 53 (42.1%) | 33 (68.8%) | 3.03 (1.50, 6.13) | 0.0017 |
| Female | 88 (50.6%) | 73 (58.0%) | 15 (31.3%) | ‐ | |
| Hemoglobin (g/dL) | |||||
| <10 | 5 (2.87%) | 1 (0.79%) | 4 (8.33%) | 11.36 (1.24, 104) | 0.0209 |
| ≥10 | 169 (97.1%) | 125 (99.2%) | 44 (91.7%) | ‐ | |
| Number of nodal sites | |||||
| ≤4 | 70 (40.5%) | 58 (46.4%) | 12 (25.0%) | 0.0102 | |
| >4 | 103 (59.5%) | 67 (53.6%) | 36 (75.0%) | 2.60 (1.24, 5.45) | |
| Stage of Disease | |||||
| Stage I‐II | 11 (6.36%) | 8 (6.35%) | 3 (6.38%) | 1.01 (0.26, 3.96) | 1.0000 |
| Stage III‐IV | 162 (93.6%) | 118 (93.7%) | 44 (93.6%) | ‐ | |
| LDH | |||||
| Below ULN | 154 (88.5%) | 117 (92.9%) | 37 (77.1%) | ‐ | 0.0035 |
| Above ULN | 20 (11.5%) | 9 (7.14%) | 11 (23.0%) | 3.86 (1.49, 10.0) | |
| Bone Marrow involvement | |||||
| No | 86 (49.4%) | 64 (50.8%) | 22 (45.8%) | ‐ | 0.5586 |
| Yes | 88 (50.6%) | 62 (49.2%) | 26 (54.2%) | 1.22 (0.63, 2.38) | |
| Node Size (cm) | |||||
| <7 | 130 (77.8%) | 101 (84.2%) | 29 (61.7%) | ‐ | 0.0017 |
| ≥7 | 37 (22.2%) | 19 (15.8%) | 18 (38.3%) | 3.30 (1.53, 7.09) | |
| Beta‐2‐Microglobulin | |||||
| Below ULN | 30 (60.0%) | 27 (62.8%) | 3 (42.9%) | ‐ | 0.4161 |
| Above ULN | 20 (40.0%) | 16 (37.2%) | 4 (57.1%) | 2.25 (0.45, 11.4) | |
| Grade 3a Disease | |||||
| No | 160 (94.1%) | 114 (92.7%) | 46 (97.9%) | 3.63 (0.45, 29.5) | 0.2874 |
| Yes | 10 (5.88%) | 9 (7.32%) | 1 (2.13%) | ‐ | |
| B symptoms Present | |||||
| No | 153 (91.6%) | 111 (91.0%) | 42 (93.3%) | 1.39 (0.37, 5.22) | 0.7611 |
| Yes | 14 (8.38%) | 11 (9.02%) | 3 (6.67%) | ‐ | |
| Albumin (g/dL) | |||||
| <3.5 | 10 (8.70%) | 3 (3.95%) | 7 (18.0%) | 5.32 (1.29, 21.9) | 0.0299 |
| ≥3.5 | 105 (91.3%) | 73 (96.1%) | 32 (82.1%) | ‐ | |
| WBC at baseline (×109 per liter) | n = 171 | n = 123 | n = 48 | ||
| Median | 6.3 | 6.4 | 6 | 1.09 (0.99, 1.21) | 0.095 |
| Range | (2.7‐77.8) | (2.7‐16.3) | (3.8‐77.8) | ||
| ALC at baseline (×109 per liter) | n = 168 | n = 121 | n = 47 | ||
| Median | 1.38 | 1.4 | 1.26 | 1.16 (0.96, 1.39) | 0.1169 |
| Range | (0.43‐41.2) | (0.43‐10.1) | (0.45‐41.2) | ||
| AMC at baseline (×109 per liter) | n = 168 | n = 121 | n = 47 | 0.0595 | |
| Median | 0.45 | 0.44 | 0.52 | 4.3 (0.94, 19.6) | |
| Range | (0.01‐3.04) | (0.01‐1.00) | (0.18‐3.04) | ||
| ALC/AMC ratio | n = 168 | n = 121 | n = 47 | ||
| Median | 3.07 | 3.15 | 2.78 | 1.03 (0.98, 1.08) | 0.2963 |
| Range | (0.83‐57) | (0.83‐57) | (0.85‐53) | ||
| FoxP3 | |||||
| Diffuse | 94 (74.0%) | 70 (76.9%) | 24 (66.7%) | ‐ | 0.3033 |
| Follicular | 3 (2.36%) | 1 (1.10%) | 2 (5.56%) | 5.83 (0.51, 67.2) | |
| M | 20 (15.8%) | 14 (15.4%) | 6 (16.7%) | 1.25 (0.43, 3.62) | |
| Partial | 10 (7.87%) | 6 (6.59%) | 4 (11.1%) | 1.94 (0.51, 7.48) | |
| PD1 | |||||
| ≤5% | 29 (31.2%) | 22 (32.4%) | 7 (28.0%) | 3.82 (0.42, 34.8) | 0.1685 |
| 6%‐33% | 51 (54.8%) | 34 (50.0%) | 17 (68.0%) | 6.00 (0.72, 50.1) | |
| >33% | 13 (14.0%) | 12 (17.7%) | 1 (4.00%) | ‐ | |
| FLIPI | |||||
| Low | 42 (24.4%) | 36 (28.8%) | 6 (12.8%) | ‐ | <0.0001 |
| Intermediate | 89 (51.7%) | 70 (56.0%) | 19 (40.4%) | 1.63 (0.60, 4.44) | |
| High | 41 (23.8%) | 19 (15.2%) | 22 (46.8%) | 6.95 (2.41, 20.1) | |
| Ki67 | n = 102 | n = 72 | n = 30 | ||
| Median | 9.24 | 9.69 | 8.92 | 0.99 (0.95, 1.03) | 0.5553 |
| Range | (0.51‐67.5) | (0.51‐67.5) | (0.59‐39.9) | ||
| CD10 (interfollicular) | |||||
| Negative | 35 (35.4%) | 30 (42.9%) | 5 (17.2%) | ‐ | |
| Positive | 64 (64.7%) | 40 (57.1%) | 24 (82.8%) | 3.60 (1.23, 10.5) | 0.0153 |
| Diagnosis to Enroll (Month) | n = 169 | n = 123 | n = 46 | ||
| Median | 1.94 | 2 | 1.87 | 1.00 (0.99, 1.03) | 0.4231 |
| Range | (0.20‐115) | (0.26‐115) | (0.20‐103) | ||
| Survival Follow‐up (Years) | n = 174 | n = 126 | n = 48 | ||
| Median | 5.4 | 5.5 | 5.1 | 0.77 (0.63, 0.94) | 0.0093 |
| Range | (0.0‐10.1) | (2.1‐10.1) | (0.0‐8.1) | ||